Stifel Nicolaus Boosts Kymera Therapeutics (NASDAQ:KYMR) Price Target to $152.00

Kymera Therapeutics (NASDAQ:KYMR) had its target price lifted by investment analysts at Stifel Nicolaus from $132.00 to $152.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price would indicate a potential upside of 29.17% from the company’s current price.

A number of other research firms have also issued reports on KYMR. Brookline Capital Markets reiterated a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 price target for the company in a report on Thursday, September 10th. Royal Bank Of Canada lowered shares of Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and lifted their price objective for the company from $106.00 to $115.00 in a research note on Monday, July 13th. Morgan Stanley restated an “overweight” rating and issued a $135.00 target price on shares of Kymera Therapeutics in a research note on Thursday, August 6th. Finally, Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $133.21.

Kymera Therapeutics Trading Down 0.1%

Shares of Kymera Therapeutics stock opened at $117.67 on Tuesday. The company has a fifty day moving average price of $114.50 and a 200 day moving average price of $97.12. Kymera Therapeutics has a twelve month low of $47.90 and a twelve month high of $130.05. The stock has a market cap of $9.78 billion, a price-to-earnings ratio of -36.32 and a beta of 1.96.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. The company had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative return on equity of 21.22% and a negative net margin of 285.33%.The firm’s revenue was up 465.2% compared to the same quarter last year. During the same period last year, the company posted ($0.95) earnings per share. Analysts forecast that Kymera Therapeutics will post -3.83 earnings per share for the current year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il sold 1,578,800 shares of the firm’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the completion of the transaction, the director directly owned 240,123 shares of the company’s stock, valued at $25,573,099.50. This trade represents a 86.80% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Bruce Jacobs sold 77,109 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the completion of the sale, the chief financial officer owned 244,883 shares in the company, valued at approximately $28,151,749.68. This trade represents a 23.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 3,080,096 shares of company stock valued at $337,948,342. 15.98% of the stock is owned by insiders.

Hedge Funds Weigh In On Kymera Therapeutics

Several large investors have recently added to or reduced their stakes in KYMR. Baker BROS. Advisors LP raised its holdings in shares of Kymera Therapeutics by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC raised its stake in Kymera Therapeutics by 17.7% during the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock worth $581,610,000 after acquiring an additional 1,124,747 shares during the period. BlackRock Inc. acquired a new position in Kymera Therapeutics in the second quarter valued at approximately $635,067,000. Capital Research Global Investors boosted its stake in Kymera Therapeutics by 23.7% in the fourth quarter. Capital Research Global Investors now owns 1,560,791 shares of the company’s stock valued at $121,445,000 after acquiring an additional 298,609 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Kymera Therapeutics by 11.0% during the 4th quarter. Geode Capital Management LLC now owns 1,417,389 shares of the company’s stock worth $110,307,000 after purchasing an additional 140,623 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that selectively remove disease-causing proteins from cells. The company’s approach is based on targeted protein degradation, which uses small-molecule degraders to direct unwanted proteins to the cell’s natural disposal system rather than simply blocking their activity.

Kymera’s research and development activities are supported by its proprietary Pegasus platform, which is designed to identify degradable proteins and create drug candidates against them.